jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Dec. 15, 2020

June. 21, 2024

jRCT2051200096

ONO-4578-03:Phase 1 study of ONO-4578 given as monotherapy and combinations of ONO-4578 and ONO-4538 as sequential treatment (neoadjuvant therapy) after chemoradiation therapy in subjects with resectable advanced rectal cancer

ONO-4578-03:ONO-4578 Phase 1 Study

Hirashima Yoshinori

Ono Pharmaceutical Co.,LTD

3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan

+81-120-626-190

clinical_trial@ono-pharma.com

Center Information Medical

Ono Pharmaceutical Co.,LTD

3 -1 -1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan

+81-120-626-190

clinical_trial@ono-pharma.com

Complete

Dec. 15, 2020

Jan. 20, 2021
30

Interventional

non-randomized controlled trial

open(masking not used)

uncontrolled control

single assignment

treatment purpose

1. Rectal adenocarcinoma
2. Patients with ECOG performance status 0 or 1

1. Patients with severe complication
2. Patients with multiple primary cancers

20age old over
80age old not

Both

Resectable rectal cancer

ONO-4578 and combinations of ONO-4578 and ONO-4538 as neoadjuvant therapy

Safety, tolerability

Ono Pharmaceutical Co.,LTD
National Hospital Organization Osaka National Hospital Institutional Review Board I
2-1-14, Hoenzaka, Chuo-ku, Osaka city, Osaka

+81-6-6942-1331

Approval

Nov. 24, 2020

No

none

History of Changes

No Publication date
6 June. 21, 2024 (this page) Changes
5 Sept. 16, 2022 Detail Changes
4 Dec. 17, 2021 Detail Changes
3 Aug. 11, 2021 Detail Changes
2 Mar. 30, 2021 Detail Changes
1 Dec. 15, 2020 Detail